Literature DB >> 18056627

The preleukemic state of mice reconstituted with Mixl1-transduced marrow cells.

Donald Metcalf1, Stefan Glaser, Sandra Mifsud, Ladina Di Rago, Lorraine Robb.   

Abstract

Murine granulocytic cells, in becoming leukemic, need to acquire enhanced self-generation and a capacity for autocrine growth stimulation. Mice transplanted with bone marrow cells transduced with the Mixl1 homeobox gene develop a very high frequency of myeloid leukemia derived from the transduced cells. Preleukemic mice contained a high frequency of transduced clonogenic granulocytic cells. They exhibited an abnormally high capacity for self-replication and could generate immortalized granulocytic cell lines that remained absolutely dependent on either GM-CSF or IL-3 and were not leukemic. Organs from mice repopulated by marrow cells transduced either with Mixl1 or the control murine stem cell virus vector exhibited a capacity to produce IL-3 in vitro, activity being highest with the lungs, marrow, bladder, and thymus. Supporting evidence for the in vivo production of IL-3 was the frequent development of mast cells in the marrow. Overexpression of Mixl1 appears capable of inducing an abnormal self-renewal capacity in granulocytic precursors. Aberrant production of IL-3 was not present in the continuous Mixl cell lines and was therefore not in itself likely to be a leukemogenic change but it could support the enhanced survival and proliferation of the Mixl1 granulocytic populations until a final leukemogenic mutation occurs in them.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18056627      PMCID: PMC2148414          DOI: 10.1073/pnas.0710339104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  19 in total

1.  Enhanced suppression of human myeloid leukemic cell lines by combinations of IL-6, LIF, GM-CSF and G-CSF.

Authors:  T Maekawa; D Metcalf; D P Gearing
Journal:  Int J Cancer       Date:  1990-02-15       Impact factor: 7.396

2.  The multi-organ origin of interleukin-5 in the mouse.

Authors:  P J Ryan; T Willson; W S Alexander; L Di Rago; S Mifsud; D Metcalf
Journal:  Leukemia       Date:  2001-08       Impact factor: 11.528

3.  In vitro actions on hemopoietic cells of recombinant murine GM-CSF purified after production in Escherichia coli: comparison with purified native GM-CSF.

Authors:  D Metcalf; A W Burgess; G R Johnson; N A Nicola; E C Nice; J DeLamarter; D R Thatcher; J J Mermod
Journal:  J Cell Physiol       Date:  1986-09       Impact factor: 6.384

4.  Molecular interactions involved in HOXB4-induced activation of HSC self-renewal.

Authors:  Nathalie Beslu; Jana Krosl; Mélanie Laurin; Nadine Mayotte; Keith R Humphries; Guy Sauvageau
Journal:  Blood       Date:  2004-06-29       Impact factor: 22.113

5.  Quantitative responsiveness of murine hemopoietic populations in vitro and in vivo to recombinant multi-CSF (IL-3).

Authors:  D Metcalf; C G Begley; N A Nicola; G R Johnson
Journal:  Exp Hematol       Date:  1987-03       Impact factor: 3.084

6.  Homeobox gene expression plus autocrine growth factor production elicits myeloid leukemia.

Authors:  A Perkins; K Kongsuwan; J Visvader; J M Adams; S Cory
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

7.  Leukemic transformation of immortalized FDC-P1 cells engrafted in GM-CSF transgenic mice.

Authors:  D Metcalf; J E Rasko
Journal:  Leukemia       Date:  1993-06       Impact factor: 11.528

8.  Nonneoplastic hematopoietic myeloproliferative syndrome induced by dysregulated multi-CSF (IL-3) expression.

Authors:  J M Chang; D Metcalf; R A Lang; T J Gonda; G R Johnson
Journal:  Blood       Date:  1989-05-01       Impact factor: 22.113

9.  In vivo transformation of factor-dependent hemopoietic cells: role of intracisternal A-particle transposition for growth factor gene activation.

Authors:  U Dührsen; J Stahl; N M Gough
Journal:  EMBO J       Date:  1990-04       Impact factor: 11.598

10.  The homeobox gene CDX2 is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesis.

Authors:  Claudia Scholl; Dimple Bansal; Konstanze Döhner; Karina Eiwen; Brian J P Huntly; Benjamin H Lee; Frank G Rücker; Richard F Schlenk; Lars Bullinger; Hartmut Döhner; D Gary Gilliland; Stefan Fröhling
Journal:  J Clin Invest       Date:  2007-03-08       Impact factor: 14.808

View more
  6 in total

1.  Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia.

Authors:  Stefan P Glaser; Erinna F Lee; Evelyn Trounson; Philippe Bouillet; Andrew Wei; W Douglas Fairlie; David J Izon; Johannes Zuber; Amy R Rappaport; Marco J Herold; Warren S Alexander; Scott W Lowe; Lorraine Robb; Andreas Strasser
Journal:  Genes Dev       Date:  2012-01-15       Impact factor: 11.361

2.  Mixl1 localizes to putative axial stem cell reservoirs and their posterior descendants in the mouse embryo.

Authors:  Adam D Wolfe; Karen M Downs
Journal:  Gene Expr Patterns       Date:  2014-03-12       Impact factor: 1.224

3.  Concordant mast cell and basophil production by individual hematopoietic blast colony-forming cells.

Authors:  Donald Metcalf; Ashley P Ng; Tracey M Baldwin; Ladina Di Rago; Sandra Mifsud
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-13       Impact factor: 11.205

4.  Two distinct types of murine blast colony-forming cells are multipotential hematopoietic precursors.

Authors:  D Metcalf; K T Greig; C A de Graaf; S J Loughran; W S Alexander; M Kauppi; C D Hyland; L Di Rago; S Mifsud
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-14       Impact factor: 11.205

5.  Reversible growth factor dependency and autonomy during murine myelomonocytic leukemia induced by oncogenes.

Authors:  Donald Metcalf; Stefan P Glaser; Zhen Xu; Ladina Di Rago; Sandra Mifsud
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-30       Impact factor: 11.205

6.  A role for BMP-induced homeobox gene MIXL1 in acute myelogenous leukemia and identification of type I BMP receptor as a potential target for therapy.

Authors:  Aaron Raymond; Bin Liu; Hong Liang; Caimiao Wei; Michele Guindani; Yue Lu; Shoudan Liang; Lisa S St John; Jeff Molldrem; Lalitha Nagarajan
Journal:  Oncotarget       Date:  2014-12-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.